Dec 09, 2020 / 01:00PM GMT
George Farmer - BMO Capital Markets Equity Research - Analyst
Hi. Good morning, everyone, and welcome to the second day of BMO's Growth and ESG Conference. My name is George Farmer. I'm senior biotechnology analyst in -- with BMO. And it is my pleasure today to have us -- have with us Lavina Talukdar, who's the Senior Vice President and Head of Investor Relations for Moderna.
Moderna is an extremely exciting company, certainly very high-profile in the news lately on the forefront of coronavirus research. Moderna, as everyone knows, has one of the leading vaccine candidates in development. We saw some very exciting Phase III results from the company released not too long ago. But Moderna is certainly much more than just its coronavirus vaccine candidate, and we hope to dig into a little bit of that as well. But I do want to dedicate most of our time here to talking about the latest in the corona vaccine research space.
Questions and Answers:
George Farmer - BMO Capital Markets Equity Research - AnalystAlong those lines, maybe we could start off,